GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Heron Therapeutics
Heron Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of chemotherapy-induced nausea and post-operative pain. Its stock price reflects the success of its product commercialization and competition in these markets.
Share prices of companies in the market segment - General oncology therapy
Heron Therapeutics develops drugs to combat chemotherapy side effects, such as nausea, and for post-operative pain relief. We've classified it in the "General Oncology" category. The chart below shows how the market values companies that improve the quality of life for cancer patients.
Broad Market Index - GURU.Markets
Heron Therapeutics develops drugs to combat chemotherapy side effects, such as nausea, and for post-operative pain relief. It is a component of the GURU.Markets index. The chart below shows the market. See how this company's stock compares to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
HRTX - Daily change in the company's share price Heron Therapeutics
Shares of Heron, a biopharmaceutical company, are highly volatile. change_co tracks investor reactions to news about its drug sales and regulatory decisions. This metric is the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Heron Therapeutics, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to HRTX, which focuses on oncology and postoperative pain management, helps assess its risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Heron is a biopharmaceutical company specializing in oncology and pain management drugs. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects the average fluctuations in this industry, providing context for evaluating Heron shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Heron Therapeutics
Heron Therapeutics' year-over-year performance tells the story of its commercialization of drugs for post-operative pain and nausea. Its market cap change over the past 12 months reflects how successfully the company is promoting its innovative products in the conservative hospital market, a key challenge for its commercial team.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Heron Therapeutics, Inc. is a commercial biopharmaceutical company focused on the treatment of chemotherapy-induced pain and nausea. The chart shows how its success in commercializing approved drugs and R&D results impact its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Heron is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Heron Therapeutics
The value of Heron, a pharmaceutical company, depends on its product cycle. The monthly fluctuations in the chart reflect sales data for its chemotherapy-induced nausea prevention and postoperative pain relief drugs, the commercial success of which determines its growth.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Heron Therapeutics develops drugs to combat the side effects of chemotherapy and for post-operative pain relief. This pharmaceutical segment aims to improve patients' quality of life. The chart shows how the market assessed the commercial potential of maintenance therapy in oncology and surgery, which is an important part of the treatment process.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Heron Therapeutics is a commercial biotech company whose drugs help cancer patients cope with the side effects of chemotherapy. Its stock price depends on sales of these drugs and competition. This is a story about commercialization, not future discoveries.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Heron Therapeutics
Shares of Heron Therapeutics, which specializes in drugs for the treatment of postoperative pain and chemotherapy-related nausea, are news-sensitive. Weekly price movements depend on sales data and regulatory decisions. The chart below shows how short-term commercial and regulatory events affect the company's valuation.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
How typical are Heron Therapeutics' dynamics for the pharmaceutical sector? This chart compares the company's weekly stock price movements with the industry average. This helps us understand whether its reaction to sales news for maintenance oncology drugs is typical, or whether its niche specialization is creating a unique trajectory.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Heron Therapeutics develops drugs to combat chemotherapy side effects such as nausea. This chart compares its weekly performance to the market. It helps us understand how much its stock depends on the success of its commercial products and the decisions of insurance companies, rather than on general market trends.
Market capitalization of the company, segment and market as a whole
HRTX - Market capitalization of the company Heron Therapeutics
Heron Therapeutics' market capitalization is the valuation of its drugs for treating chemotherapy side effects, such as nausea, and post-operative pain. The company's value depends on the commercial success of its already approved products. The chart shows how investors assess its ability to compete in these markets.
HRTX - Share of the company's market capitalization Heron Therapeutics within the market segment - General oncology therapy
Heron Therapeutics is building its market share by developing drugs to treat chemotherapy-induced nausea and post-operative pain. Its market capitalization reflects both the commercial success of its products and the challenges associated with bringing new drugs to market.
Market capitalization of the market segment - General oncology therapy
This chart shows the total value of pharmaceutical companies specializing in supportive care in oncology. Heron Therapeutics is the leader in this niche. The dynamics in the chart reflect the importance of the market for drugs that combat the side effects of cancer treatment rather than cancer itself.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a market valuation of the treatment of side effects associated with cancer treatment. Heron Therapeutics' market capitalization is based on the valuation of its drugs for treating nausea and pain associated with chemotherapy. The chart shows the importance of maintenance therapy, which improves patients' quality of life, in the global healthcare economy.
Book value capitalization of the company, segment and market as a whole
HRTX - Book value capitalization of the company Heron Therapeutics
This chart shows the scientific foundation of Heron Therapeutics. Its line reflects the value of intellectual property for drugs for postoperative pain relief and the prevention of nausea during chemotherapy. The trend reflects the commercial success of approved drugs, which are the company's main asset.
HRTX - Share of the company's book capitalization Heron Therapeutics within the market segment - General oncology therapy
Heron Therapeutics' physical infrastructure includes R&D centers and contract manufacturing for the development of drugs aimed at combating the side effects of chemotherapy and post-operative pain. The chart shows its share of this pharmaceutical base, which is focused on maintenance therapy.
Market segment balance sheet capitalization - General oncology therapy
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Heron, with its focus on oncology and post-operative care drugs, is moderately capital-intensive. Commercializing its products requires investments in marketing and supply chains, which weighs down its balance sheet compared to R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Heron Therapeutics develops drugs for oncology and post-operative pain relief. The company's assets include FDA-approved drugs and commercial infrastructure. The company's balance sheet is the value of solving two very important and real medical problems: nausea during chemotherapy and pain after surgery.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Heron Therapeutics
Heron's balance sheet consists of its cash and approved drugs. A market valuation below its book value reflects weak sales and intense competition. A MvsBCap_Co < 1 chart indicates the market doesn't believe these drugs will generate enough profit to recoup the assets.
Market to book capitalization ratio in a market segment - General oncology therapy
Heron Therapeutics develops drugs to combat chemotherapy side effects (nausea) and post-operative pain. The chart shows how the market evaluates its commercial products and their ability to capture share in the competitive hospital drug market.
Market to book capitalization ratio for the market as a whole
Heron Therapeutics develops drugs to improve patients' quality of life, primarily to prevent chemotherapy-induced nausea and vomiting and for post-operative pain relief. This chart helps assess how the market perceives companies focused on supportive care in oncology.
Debts of the company, segment and market as a whole
HRTX - Company debts Heron Therapeutics
For Heron Therapeutics, a company developing drugs for maintenance therapy in oncology, debt is a tool for commercialization. This chart shows how the company raises capital to market and sell its products to combat nausea and pain after chemotherapy. Debt here is the bridge between FDA approval and widespread adoption.
Market segment debts - General oncology therapy
Heron Therapeutics develops drugs to improve patients' quality of life, specifically to combat chemotherapy-induced nausea and vomiting and for post-operative pain relief. This chart shows how the pharmaceutical company funds the commercialization of its already approved products and the development of new candidates.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Heron Therapeutics
Heron Therapeutics develops drugs for oncology and post-operative pain management. This chart shows the company's balance between debt and equity. For a pharmaceutical company whose revenue depends on the commercial success of several products, debt levels are an important indicator of its ability to fund marketing and further research.
Market segment debt to market segment book capitalization - General oncology therapy
Heron Therapeutics develops drugs to combat the side effects of chemotherapy (nausea) and post-operative pain. Commercializing such products requires significant investment. The chart shows how the company's debt load compares to the overall market capitalization of the oncology and pharmaceutical sectors.
Debt to book value of all companies in the market
Heron Therapeutics (HRTX) develops and commercializes drugs to improve patients' quality of life, such as those used to combat nausea associated with chemotherapy. The company already has approved products. This chart shows the market's overall debt load. It allows one to compare HRTX's financial strategy, which is already profitable, with that of earlier-stage companies.
P/E of the company, segment and market as a whole
P/E - Heron Therapeutics
For Heron Therapeutics, a company focused on maintenance therapy drugs in oncology (e.g., anti-nausea), this chart shows the valuation in this important but competitive market. The P/E is dependent on the successful launch and sales of its products. A decline could be due to slow drug adoption or competitive pressure.
P/E of the market segment - General oncology therapy
This industry metric represents the average P/E for pharmaceutical companies. For Heron, with its focus on supportive care in oncology, it's an important benchmark. Comparing its P/E to the sector average helps understand how investors evaluate the commercial potential of its products in this competitive market.
P/E of the market as a whole
Heron Therapeutics is a commercial pharmaceutical company focused on improving patients' lives by developing treatments for chemotherapy-induced nausea and vomiting, as well as post-operative pain. This sentiment chart helps understand how investors value companies in the supportive care space.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Heron Therapeutics
Heron Therapeutics is a commercial biotechnology company focused on drugs for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. This graph reflects sales expectations for its already approved products. Estimates are dependent on the success of their commercialization and competition in the oncology maintenance therapy market.
%20P%2FE%20Heron%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Heron-Therapeutics&v=1772688735479 "Chart of the company's future (projected) P/E Heron Therapeutics")
Future (projected) P/E of the market segment - General oncology therapy
Heron Therapeutics develops treatments to improve patients' quality of life, primarily in oncology and post-operative pain management. This chart compares the company's future profitability expectations with the pharmaceutical sector average. It reflects the market's confidence in the commercial success of their nausea and pain management products.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772688735509 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Heron Therapeutics develops drugs to treat chemotherapy-induced nausea and vomiting, as well as post-operative pain relief. The company's success depends on the commercialization of its products. This market expectations chart influences Heron through the overall assessment of the biotech sector and investor sentiment toward pharmaceutical companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772688735551 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Heron Therapeutics
Heron Therapeutics is a commercial biotechnology company that develops and markets drugs to combat the side effects of chemotherapy (nausea) and for post-operative pain relief. Its profits depend on successful sales of already approved products and competition in these markets.
Profit of companies in the market segment - General oncology therapy
Heron Therapeutics develops drugs to combat the side effects of chemotherapy (nausea) and post-operative pain. The company addresses important supportive needs in medicine. This chart shows how drugs that improve patients' quality of life form an important and stable segment of the pharmaceutical market, influencing its overall profitability.
Overall market profit
Heron Therapeutics develops medications to treat chemotherapy-induced nausea and vomiting, as well as post-operative pain relief. Demand for these maintenance medications is driven by the number of cancer patients and surgical procedures, not the state of the economy. This makes Heron's business non-cyclical.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Heron Therapeutics
Heron Therapeutics specializes in drugs for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. The future profit projections shown in this chart depend on the commercial success of its products and their ability to compete with other treatments on the market.
%20profit%20of%20the%20company%20Heron%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Heron-Therapeutics&v=1772688735656 "Graph of future (projected) profit of the company Heron Therapeutics")
Future (predicted) profit of companies in the market segment - General oncology therapy
Heron Therapeutics is a commercial pharmaceutical company whose products target chemotherapy side effects, such as nausea, and post-surgical pain relief. This chart shows the revenue forecast for the general oncology and supportive care sector. It reflects expected demand for drugs that improve patients' quality of life.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772688735688 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Heron Therapeutics develops medications to combat the side effects of chemotherapy (nausea) and for postoperative pain relief. Demand for its products depends on the number of surgeries and chemotherapy courses performed. The economic forecasts presented here may impact the number of elective surgeries and the availability of advanced supportive care medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772688735698 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Heron Therapeutics
Heron Therapeutics is a commercial-stage biotech company focused on drugs for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. This chart shows how investors view its current sales and ability to successfully launch new products in the competitive hospital environment.
P/S market segment - General oncology therapy
Heron Therapeutics is a commercial pharmaceutical company specializing in medications for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. This chart shows the average valuation in the sector, which helps understand how the market views Heron's product portfolio and commercial prospects.
P/S of the market as a whole
Heron Therapeutics is a commercial pharmaceutical company specializing in oncology maintenance therapy (anti-nausea and vomiting) and post-operative pain relief. This market valuation chart helps understand how investors view the company, whose revenue depends on the successful commercialization of its already approved drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Heron Therapeutics
Heron Therapeutics develops drugs to treat chemotherapy-induced nausea and vomiting, as well as post-operative pain. Future revenue depends on sales of its already approved products. This chart shows how investors assess the commercial potential of its drugs in the maintenance therapy market.
%20P%2FS%20Heron%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Heron-Therapeutics&v=1772688735796 "The graph of the company's future (projected) P/S Heron Therapeutics")
Future (projected) P/S of the market segment - General oncology therapy
Heron Therapeutics develops drugs to treat chemotherapy-induced nausea and vomiting, as well as post-operative pain relief. This chart compares market expectations for its future revenue with those of other oncology companies. This estimate reflects investor opinion on the commercial potential of its approved products.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772688735822 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Heron Therapeutics develops drugs to combat the side effects of chemotherapy (nausea) and for post-operative pain relief. The company's success depends on the acceptance of its products by doctors. Market optimism, as seen in this chart, influences hospital budgets and their willingness to use new, more effective, albeit more expensive, supportive medications.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772688735829 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Heron Therapeutics
Heron Therapeutics is a commercial biotechnology company focused on drugs for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. The company's revenue comes from sales of its approved drugs. The chart shows their commercial success and demand from hospitals and oncology clinics.
Sales of companies in the market segment - General oncology therapy
Heron Therapeutics is a commercial pharmaceutical company focused on drugs for maintenance therapy in oncology and postoperative pain management. Its portfolio includes several approved products. Revenue is generated from sales of these drugs. This chart shows the state of markets where innovation is aimed not at treating the disease itself, but at improving patients' quality of life.
Overall market sales
Heron Therapeutics develops drugs for maintenance therapy in oncology (anti-nausea) and post-operative pain management. Demand for its products depends on the number of surgeries and chemotherapy courses performed. This business is less cyclical, but the financial health of hospitals, which is influenced by the economy, influences the introduction of new drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Heron Therapeutics
Heron Therapeutics is a commercial pharmaceutical company focused on drugs for maintenance therapy in oncology (anti-nausea) and post-operative pain management. This chart shows analysts' expectations for sales of the company's already approved products and their ability to gain market share.
%20sales%20of%20the%20company%20Heron%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Heron-Therapeutics&v=1772688735892 "Schedule of future (projected) sales of the company Heron Therapeutics")
Future (projected) sales of companies in the market segment - General oncology therapy
Heron Therapeutics develops drugs to improve patients' quality of life, primarily in oncology and postoperative pain management. This chart illustrates expectations for the oncology therapeutics sector. It helps analyze how the company's products, aimed at combating chemotherapy-induced nausea and pain, address important unmet medical needs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772688735900 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Heron Therapeutics develops medications to control chemotherapy-induced nausea and vomiting, as well as for post-operative pain relief. This graph, reflecting healthcare costs, is important to the company. Stable funding for hospitals and cancer centers ensures demand for medications that improve patients' quality of life during treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772688735935 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Heron Therapeutics
Heron Therapeutics is a commercial pharmaceutical company focused on improving the lives of cancer patients. It develops drugs to combat chemotherapy side effects such as nausea and pain. This chart shows how the company converts its approved drugs into revenue by solving important but often overlooked problems in oncology.
Market segment marginality - General oncology therapy
Heron Therapeutics specializes in maintenance therapy drugs in oncology, specifically for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. This chart shows the company's success in commercializing its products in these important niches that improve patients' quality of life.
Market marginality as a whole
Heron Therapeutics is a commercial pharmaceutical company focused on products for oncology maintenance therapy (anti-nausea) and post-operative pain relief. Unlike early-stage biotechs, their profitability depends on successful sales of already approved drugs and competition in these markets.
Employees in the company, segment and market as a whole
Number of employees in the company Heron Therapeutics
Heron Therapeutics is a commercial pharmaceutical company focused on maintenance therapy in oncology and postoperative pain management. This chart shows the commercial and R&D teams. The size of the team reflects the efforts to advance approved products and develop new ones.
Share of the company's employees Heron Therapeutics within the market segment - General oncology therapy
Heron Therapeutics develops drugs to improve patients' quality of life, primarily in oncology and post-operative pain management. This chart shows its market share in the pharmaceutical sector. It reflects the team working on new solutions to combat side effects such as nausea, vomiting, and pain.
Number of employees in the market segment - General oncology therapy
Heron Therapeutics develops drugs to improve quality of life for cancer patients, specifically to combat chemotherapy-induced nausea. This chart shows employment in the oncology supportive care sector. A stable clinical and commercial workforce reflects the company's focus on addressing important unmet patient needs.
Number of employees in the market as a whole
Heron Therapeutics is a commercial pharmaceutical company focused on drugs for the treatment of chemotherapy-induced nausea and vomiting, as well as postoperative pain relief. This chart reflects overall employment, and companies like Heron are solving important supporting problems in medicine, creating jobs in sales, marketing, and clinical research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Heron Therapeutics (HRTX)
Heron Therapeutics, Inc. is a commercial pharmaceutical company selling medications for the treatment of nausea and post-surgical pain. Its business model is based on patented products. This chart demonstrates its high capitalization per employee. A small sales and marketing team can market a product with multimillion-dollar revenues, demonstrating the effectiveness of its intellectual property.
%20of%20the%20company%20Heron%20Therapeutics%20(HRTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Heron-Therapeutics-HRTX&v=1772688736346 "Chart of market capitalization per employee (in thousands of dollars) of the company Heron Therapeutics (HRTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Heron Therapeutics develops drugs to treat chemotherapy-induced nausea and vomiting, as well as for postoperative pain relief. This is an important supportive therapy in medicine. The chart shows how the market perceives the commercial potential of its approved products. The cost per employee reflects the effectiveness of its commercial team.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772688736353 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Heron Therapeutics develops drugs for maintenance therapy in oncology, specifically to combat chemotherapy-induced nausea and post-operative pain. This chart shows how the market evaluates the company's ability to commercialize products that improve the quality of life for cancer patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772688736378 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Heron Therapeutics (HRTX)
Heron Therapeutics (HRTX) is a biopharmaceutical company focused on hospital-grade medications (post-surgical pain management, chemotherapy-induced nausea). This chart shows how successfully their small sales team is commercializing these niche hospital-grade medications.
%20Chart%20Heron%20Therapeutics%20(HRTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Heron-Therapeutics-HRTX&v=1772688736386 "Company Profit Per Employee (in thousands of dollars) Chart Heron Therapeutics (HRTX)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Heron Therapeutics commercializes drugs for the treatment of chemotherapy-induced nausea, as well as non-opioid painkillers. Their business is focused on hospital medications. This chart shows the benchmark for employee profitability in the pharmaceutical industry. It is important for assessing how effectively the Heron team is monetizing its products.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772688736393 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Heron Therapeutics (HRTX) is a commercial pharmaceutical company focused on maintenance therapy (e.g., anti-nausea medications for chemotherapy) and pain management (long-acting medications after surgery). They have approved products. This chart shows how effectively their commercial team (sales department) sells these drugs to hospitals.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772688736411 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Heron Therapeutics (HRTX)
Heron Therapeutics is a commercial pharmaceutical company focused on drugs for the treatment of chemotherapy-induced nausea and post-operative pain. This chart shows the effectiveness of its commercial efforts, demonstrating how successfully its sales and marketing team promotes approved drugs to physicians and hospitals.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Heron-Therapeutics-HRTX&v=1772688736424 "Sales chart per company employee Heron Therapeutics (HRTX)")
Sales per employee in the market segment - General oncology therapy
Heron Therapeutics (HRTX) is a pharmaceutical company focused on maintenance therapy drugs in oncology (to prevent nausea) and postoperative pain relief. This chart shows how much revenue each employee generates from sales of their commercial products. This is an indicator of their commercial performance.
Sales per employee for the market as a whole
Heron Therapeutics (HRTX) is a commercial biotech company. They have approved drugs to prevent nausea after chemotherapy, as well as non-opioid painkillers. This chart shows how successfully their commercial team is selling these specialized hospital drugs, generating revenue in niche but important medical segments.
Short shares by company, segment and market as a whole
Shares shorted by company Heron Therapeutics (HRTX)
Heron Therapeutics is a biopharmaceutical company focused on drugs for the treatment of post-operative pain and chemotherapy-induced nausea. This chart shows bearish bets. The shorts may be due to the weak commercial launch of their pain medications, which failed to compete with existing treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Heron-Therapeutics-HRTX&v=1772688736465 "Short Shares Chart for the Company Heron Therapeutics (HRTX)")
Shares shorted by market segment - General oncology therapy
Heron Therapeutics (HRTX) is a pharmaceutical company focused on oncology maintenance therapy (anti-nausea/vomiting) and post-operative pain relief. This chart shows bets against the specialty pharmaceutical sector. The rising bets against the industry may reflect investor concerns about the slow commercial adoption of pain medications.
Shares shorted by the overall market
Heron Therapeutics develops drugs for oncology and post-surgical pain relief. The company has commercial products but has not yet achieved stable profitability. Although healthcare is a defensive sector, the surge in general market fears (shown here) is still putting pressure on biotech companies dependent on market financing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Heron Therapeutics (HRTX)
Heron Therapeutics is developing drugs to treat pain and nausea after chemotherapy. Success depends on approval and sales. This chart can soar above 70 on positive FDA news or strong sales. A range below 30 is often associated with setbacks, delays, or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Heron-Therapeutics-HRTX&v=1772688736499 "RSI 14 indicator chart for the company's stock Heron Therapeutics (HRTX)")
RSI 14 Market Segment - General oncology therapy
Heron Therapeutics is a pharmaceutical company with two distinct missions: it produces drugs for oncology maintenance therapy (anti-nausea) and non-opioid anesthetics for post-operative pain. This chart shows the overall sentiment in the oncology and specialty pharmaceutical sectors. It helps us understand whether the HRTX trend is driven by its sales or is a general "wave" in the industry.
RSI 14 for the overall market
Heron Therapeutics (HRTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HRTX (Heron Therapeutics)
Heron Therapeutics is a biopharmaceutical company focused on cancer treatment and post-surgical pain. Its products (Cinvanti and Aponvie) combat nausea, and Zynrelef is a non-opioid pain reliever. This chart shows the average price target from analysts assessing the commercialization rates of these drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HRTX-Heron-Therapeutics&v=1772688736547 "A chart showing analyst consensus forecasts for the expected stock price. HRTX (Heron Therapeutics)")
The difference between the consensus estimate and the actual stock price HRTX (Heron Therapeutics)
Heron (HRTX) is a pharmaceutical company focused on maintenance therapy. Its products don't target cancer, but rather its consequences: nausea (Cinvanti) and post-operative pain (Zynrelef). This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the commercial success of these drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HRTX-Heron-Therapeutics&v=1772688736552 "A chart showing the difference between the consensus forecast and the actual stock price. HRTX (Heron Therapeutics)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Heron (HRTX) is a pharmaceutical company focused on maintenance therapy. Its drugs help cancer patients combat nausea from chemotherapy (Cinvanti) and post-operative pain. This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe the market for patient "quality of life," not just treatment, will grow.
Analysts' consensus forecast for the overall market share price
Heron is a "niche" pharma. They "focus" on "maintenance" "therapy" (e.g., "nausea" "during" "chemo") and "non-opioid" "pain relief." This chart of overall market sentiment is important. Demand is "protected" (people are "treating" "cancer"). In a "recession" (pessimism), "investors" "appreciate" the "non-cyclical" nature of HRTX's "business."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Heron Therapeutics
Heron (HRTX) is a biopharmaceutical company focused on maintenance therapy. Their specialty is long-acting medications for two niches: nausea prevention (Cinvanti) and non-opioid post-operative pain relief (Zynrelef). This chart is an adoption indicator. It measures their ability to convince hospitals to use their (more expensive) medications instead of older generics.
AKIMA Market Segment Index - General oncology therapy
Heron Therapeutics specializes in maintenance therapy drugs in oncology, primarily for chemotherapy-induced nausea and post-operative pain. This chart shows the average index for the oncology sector. It allows one to assess how Heron, with its focus on patient quality of life, compares to the industry average.
The AKIM Index for the overall market
Heron Therapeutics is a commercial-stage biotech company offering opioid-free treatments for acute pain and nausea associated with chemotherapy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, focused on sales and profitability, compares to overall economic trends.
